Article
Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma.
Leukemia - 1 Mar 2022
Newman Alexander M, Zaka Masood, Zhou Peixun, Blain Alex E, Erhorn Amy, Barnard Amy, Crossland Rachel E, Wilkinson Sarah, Enshaei Amir, De Zordi Julian, Harding Fiona, Taj Mary, Wood Katrina M, Televantou Despina, Turner Suzanne D, Burke G A Amos, Harrison Christine J, Bomken Simon, Bacon Chris M, Rand Vikki
Abstract excerpt
Children with B-cell non-Hodgkin lymphoma (B-NHL) have an excellent chance of survival, however, current clinical risk stratification places as many as half of patients in a high-risk group receiving very intensive chemo-immunotherapy. TP53 alterations are associated with adverse outcome in many malignancies; however, whilst common in paediatric B-NHL, their utility as a risk classifier is unknown. We evaluated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.